SVA

+ Watchlist + Portfolio

Sinovac Biotech, Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.47
52-Week Range: $6.47 – $6.47
Market Cap: —
P/E (TTM): 6.66
EPS (TTM): —
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: —
Operating Margin: —
Profit Margin: —
Current Ratio: —
Debt/Equity: —
Total Debt: —
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: —

SVA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.49B	$470.17M	$361.37M	$386.01M
Cost of Revenue	$684.46M	$146.85M	$140.69M	$124.03M
Gross Profit	$808.30M	$323.32M	$220.69M	$261.98M
Research & Development	$442.11M	$350.19M	$270.66M	$216.18M
Selling, General & Admin	$823.54M	$598.25M	$420.92M	$332.98M
Operating Expenses	$1.27B	$928.58M	$695.94M	$549.27M
Operating Income	-$460.85M	-$605.26M	-$475.26M	-$287.29M
EBITDA	$183.10M	$81.19M	$162.01M	-$151.25M
Pretax Income	$25.24M	-$84.49M	$42.84M	-$262.10M
Income Tax	-$62.89M	$36.37M	$2.18M	-$63.27M
Net Income	$113.87M	-$13.49M	$90.91M	-$59.68M
Diluted EPS	1.00	-0.19	1.27	-0.83
Diluted Shares	114.17M	71.85M	71.86M	71.86M

SVA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.28B	$1.27B	$335.27M	$488.25M
Receivables	$609.49M	$450.72M	$316.33M	$313.09M
Inventory	$180.72M	$139.87M	$96.92M	$94.31M
Current Assets	$12.13B	$11.83B	$10.64B	$7.06B
Total Assets	$14.11B	$13.66B	$12.34B	$8.54B
Current Liabilities	$1.09B	$1.15B	$1.45B	$1.54B
Long-Term Debt	$11.51M	$177.82M	$163.84M	$265.48M
Total Debt	$74.67M	$298.98M	$391.32M	$505.62M
Total Liabilities	$1.40B	$1.64B	$2.04B	$2.15B
Retained Earnings	$7.23B	$7.12B	$6.84B	$2.82B
Shareholders' Equity	$8.92B	$8.71B	$8.26B	$4.44B
Working Capital	$11.03B	$10.68B	$9.19B	$5.52B
Net Debt	—	—	$40.49M	$6.61M

SVA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$770.75M	$138.65M	-$56.89M	-$512.18M
Capital Expenditure	-$403.37M	-$156.21M	-$97.59M	-$49.12M
Free Cash Flow	-$1.17B	-$17.56M	-$154.48M	-$561.30M
Depreciation & Amortisation	$156.60M	$160.73M	$113.54M	$101.04M
Stock-Based Compensation	$0.00	$0.00	—	—
Investing Cash Flow	-$5.76B	-$2.70B	$456.36M	$4.39B
Financing Cash Flow	-$241.40M	-$88.55M	-$823.95M	-$3.43B
Dividends Paid	-$263.17M	-$328.08M	-$947.00M	-$3.53B
Net Change in Cash	-$6.77B	-$2.65B	-$424.48M	$441.28M

SVA Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$335.27M	$182.63M	$488.25M
Receivables	$316.33M	$321.79M	$313.09M
Inventory	$96.92M	$109.14M	$94.31M
Current Assets	$10.64B	$10.38B	$7.06B
Total Assets	$12.34B	$11.99B	$8.54B
Current Liabilities	$1.45B	$5.00B	$1.54B
Long-Term Debt	$163.84M	$233.06M	$265.48M
Total Debt	$391.32M	$463.18M	$505.62M
Total Liabilities	$2.04B	$5.64B	$2.15B
Retained Earnings	$6.84B	$2.86B	$2.82B
Shareholders' Equity	$8.26B	$4.37B	$4.44B
Working Capital	$9.19B	$5.38B	$5.52B
Net Debt	$40.49M	$265.39M	$6.61M

Market Snapshot

About

Sinovac Biotech, Ltd. is a China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines. The company is known for developing vaccines against infectious diseases including hepatitis, influenza, and COVID-19. Sinovac gained international recognition during the COVID-19 pandemic with its CoronaVac vaccine.